Brazil · Delayed Price · Currency is BRL Dexco Statistics
Total Valuation
Dexco has a market cap or net worth of BRL 4.53 billion. The enterprise value is 10.96 billion.
| Market Cap | 4.53B |
| Enterprise Value | 10.96B |
Important Dates
The last earnings date was Thursday, August 6, 2026.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Dexco has 907.87 million shares outstanding. The number of shares has increased by 0.92% in one year.
| Current Share Class | 907.87M |
| Shares Outstanding | 907.87M |
| Shares Change (YoY) | +0.92% |
| Shares Change (QoQ) | -0.63% |
| Owned by Insiders (%) | 19.49% |
| Owned by Institutions (%) | 30.28% |
| Float | 279.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.67 |
| PS Ratio | 0.53 |
| PB Ratio | 0.61 |
| P/TBV Ratio | 0.73 |
| P/FCF Ratio | 10.72 |
| P/OCF Ratio | 3.39 |
| PEG Ratio | 0.07 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.31, with an EV/FCF ratio of 25.95.
| EV / Earnings | n/a |
| EV / Sales | 1.29 |
| EV / EBITDA | 5.31 |
| EV / EBIT | 12.95 |
| EV / FCF | 25.95 |
Financial Position
The company has a current ratio of 1.98, with a Debt / Equity ratio of 1.19.
| Current Ratio | 1.98 |
| Quick Ratio | 1.35 |
| Debt / Equity | 1.19 |
| Debt / EBITDA | 4.49 |
| Debt / FCF | 20.77 |
| Interest Coverage | 0.71 |
Financial Efficiency
Return on equity (ROE) is 0.73% and return on invested capital (ROIC) is 5.41%.
| Return on Equity (ROE) | 0.73% |
| Return on Assets (ROA) | 2.48% |
| Return on Invested Capital (ROIC) | 5.41% |
| Return on Capital Employed (ROCE) | 4.63% |
| Weighted Average Cost of Capital (WACC) | 8.40% |
| Revenue Per Employee | 595,627 |
| Profits Per Employee | -2,535 |
| Employee Count | 14,228 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 3.55 |
Taxes
| Income Tax | -91.28M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.74% in the last 52 weeks. The beta is 0.42, so Dexco's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -0.74% |
| 50-Day Moving Average | 4.99 |
| 200-Day Moving Average | 5.07 |
| Relative Strength Index (RSI) | 47.56 |
| Average Volume (20 Days) | 1,804,490 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Dexco had revenue of BRL 8.47 billion and -36.06 million in losses. Loss per share was -0.04.
| Revenue | 8.47B |
| Gross Profit | 2.11B |
| Operating Income | 734.47M |
| Pretax Income | -38.57M |
| Net Income | -36.06M |
| EBITDA | 1.90B |
| EBIT | 734.47M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 2.68 billion in cash and 8.77 billion in debt, with a net cash position of -5.95 billion or -6.56 per share.
| Cash & Cash Equivalents | 2.68B |
| Total Debt | 8.77B |
| Net Cash | -5.95B |
| Net Cash Per Share | -6.56 |
| Equity (Book Value) | 7.40B |
| Book Value Per Share | 7.63 |
| Working Capital | 3.19B |
Cash Flow
In the last 12 months, operating cash flow was 1.33 billion and capital expenditures -912.34 million, giving a free cash flow of 422.54 million.
| Operating Cash Flow | 1.33B |
| Capital Expenditures | -912.34M |
| Depreciation & Amortization | 1.16B |
| Net Borrowing | 467.61M |
| Free Cash Flow | 422.54M |
| FCF Per Share | 0.47 |
Margins
Gross margin is 24.89%, with operating and profit margins of 8.67% and -0.43%.
| Gross Margin | 24.89% |
| Operating Margin | 8.67% |
| Pretax Margin | -0.46% |
| Profit Margin | -0.43% |
| EBITDA Margin | 22.37% |
| EBIT Margin | 8.67% |
| FCF Margin | 4.99% |
Dividends & Yields
Dexco does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.92% |
| Shareholder Yield | -0.92% |
| Earnings Yield | -0.80% |
| FCF Yield | 9.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Dexco is 7.80, which is 56.31% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 7.80 |
| Price Target Difference | 56.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 5.23% |
| EPS Growth Forecast (3Y) | 84.29% |
Stock Splits
The last stock split was on December 26, 2025. It was a forward split with a ratio of 1.12.
| Last Split Date | Dec 26, 2025 |
| Split Type | Forward |
| Split Ratio | 1.12 |
Scores
Dexco has an Altman Z-Score of 1.11 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.11 |
| Piotroski F-Score | 6 |